Loading
A phase 1/2 trial of ivonescimab in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535463 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 53 participants, started 2026-04-10 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Stereotactic Radiosurgery. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: identify the Recommended Phase 2 Dose (RPD2); intracranial progression-free survival (iPFS),. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small cell lung cancer, including squamous and non-squamous histologies". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, SBRT / SABR (stereotactic radiotherapy) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.